SNU182_LIVER
HCC · Hepatocellular Carcinoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
- subtype
- —
- cancer_type
- HCC
- ccle_sample_id
- SNU182_LIVER
- synthetic_from_ccle
- true
- display_name
- SNU-182
- ccle_lineage
- liver
- ccle_lineage_subtype
- hepatocellular_carcinoma
- oncotree_code
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.872
- ANGIOGENESIS+0.521
- NOTCH_SIGNALING+0.429
- UV_RESPONSE_DN+0.417
- TGF_BETA_SIGNALING+0.351
- MYOGENESIS+0.342
- HEDGEHOG_SIGNALING+0.227
- COAGULATION+0.202
- WNT_BETA_CATENIN_SIGNALING+0.195
- APICAL_JUNCTION+0.182
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.727
- INTERFERON_GAMMA_RESPONSE-0.441
- E2F_TARGETS-0.259
- PEROXISOME-0.240
- G2M_CHECKPOINT-0.234
- MTORC1_SIGNALING-0.186
- BILE_ACID_METABOLISM-0.183
- FATTY_ACID_METABOLISM-0.171
- P53_PATHWAY-0.154
- ALLOGRAFT_REJECTION-0.132
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-P3-A5QA-01A-11R-A28V-07 | — | — | 0.812 |
| 2 | TCGA-P3-A6T8-01A-11R-A34R-07 | — | — | 0.800 |
| 3 | R314 | — | — | 0.798 |
| 4 | TCGA-18-3409-01A-01R-0980-07 | — | cohortSQ1 | 0.797 |
| 5 | SRR8613779 | — | D | 0.794 |
| 6 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.787 |
| 7 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.753 |
| 8 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.752 |
| 9 | SRR11296891 | — | — | 0.748 |
| 10 | TCGA-73-4668-01A-01R-1206-07 | — | cohortA1 | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.872 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.521 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.429 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.417 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.351 | Inavolisib | — uncovered |
| MYOGENESIS | 0.342 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.227 | Inavolisib | — uncovered |
| COAGULATION | 0.202 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.195 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.182 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.173 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.157 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.127 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.117 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.094 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.055 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.038 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.022 | Inavolisib | — uncovered |